Literature DB >> 8585108

Pharmacokinetic interaction between lansoprazole and theophylline.

G R Granneman1, M D Karol, C S Locke, J H Cavanaugh.   

Abstract

The pharmacokinetic interaction potential of the new proton-pump inhibitor lansoprazole and theophylline was assessed in a double-blind, two-period (13-day duration per period), multiple-dose crossover study in 14 healthy male volunteers. Lansoprazole 60 mg or placebo once daily was coadministered with anhydrous theophylline 200 mg four times daily. Plasma theophylline concentrations were quantitated via high-performance liquid chromatography. Lansoprazole did not appear to affect substantially the absorption profile or clearance of theophylline. Theophylline area under the plasma concentration-versus-time curve over the 6-h dosing interval decreased slightly (13%) but statistically significantly during lansoprazole coadministration. As the magnitude of this effect was small, this interaction is likely to be clinically insignificant.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8585108     DOI: 10.1097/00007691-199510000-00005

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  14 in total

Review 1.  Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 2.  Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors:  Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.

Authors:  T Andersson; J Holmberg; K Röhss; A Walan
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

Review 4.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

5.  The expression, induction and pharmacological activity of CYP1A2 are post-transcriptionally regulated by microRNA hsa-miR-132-5p.

Authors:  Yinting Chen; Linjuan Zeng; Yong Wang; William H Tolleson; Bridgett Knox; Si Chen; Zhen Ren; Lei Guo; Nan Mei; Feng Qian; Kaihong Huang; David Liu; Weida Tong; Dianke Yu; Baitang Ning
Journal:  Biochem Pharmacol       Date:  2017-08-16       Impact factor: 5.858

Review 6.  Formulary management of proton pump inhibitors.

Authors:  M F Byrne; F E Murray
Journal:  Pharmacoeconomics       Date:  1999-09       Impact factor: 4.981

Review 7.  Pharmacokinetic drug interactions with anti-ulcer drugs.

Authors:  R D Negro
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

Review 8.  Drug-drug interaction profiles of proton pump inhibitors.

Authors:  Ryuichi Ogawa; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

9.  Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment.

Authors:  Benjamin D Gold; James W Freston
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

10.  Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.

Authors:  Majid Vakily; Ronald D Lee; Jingtao Wu; Lhanoo Gunawardhana; Darcy Mulford
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.